SERPINF1 / PEDF antibody Ab
- Known as:
- SERPINF1 / PEDF (anti-) Antibody
- Catalog number:
- 1487989
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Acris antibodies
- Gene target:
- SERPINF1 / PEDF antibody
Related genes to: SERPINF1 / PEDF antibody Ab
- Gene:
- SERPINF1 NIH gene
- Name:
- serpin family F member 1
- Previous symbol:
- PEDF
- Synonyms:
- EPC-1, PIG35
- Chromosome:
- 17p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-05-18
- Date modifiied:
- 2018-03-02
Related products to: SERPINF1 / PEDF antibody Ab
Related articles to: SERPINF1 / PEDF antibody Ab
- This study was performed to determine whether angiopoietin (Ang)-1 and Ang-2 influence the survival of retinal neurons via Müller cell-mediated mechanisms. - Source: PubMed
Younis RuaaMüller HeidiZiemssen FockeEichler Wolfram - The egg laying process of poultry is determined by follicular development. In the present study, hens with lower egg production rates had significantly fewer small white follicles than those with higher rates. In order to investigate the regulatory mechanisms governing the development from white follicles to yellow follicles, transcriptome sequencing was performed on small white follicles (SWFs), small yellow follicles (SYFs) and F6 (the smallest hierarchical follicles) of high-yield laying hens. Pathways enrichment analysis revealed that the vascular endothelial growth factor (VEGF) signaling, peroxisome proliferator-activated receptor (PPAR) signaling, tight junction and gap junction pathways, as well as steroid hormone biosynthesis were involved in follicular development. Compared with the transition from SYFs to F6, the transition from SWFs to SYFs showed more pronounced changes in gene expression profiles. This was validated by Western blot analysis, which revealed significantly upregulated expression of angiogenesis-related proteins (VEGF, VEGFR1, VEGFR2, ANGPT1 and ANGPT2) and downregulated expression of pigment epithelium derived factor (PEDF) in SYFs compared to SWFs. Immunofluorescence staining (IF) confirmed a markedly higher CD31-positive staining area in the theca layer of SYFs than in that of SWFs. Meanwhile, the estradiol (E) and progesterone (P) levels in SYFs increased by 131.6% and 22.2%, respectively, compared to SWFs. At the transcript level, SYFs exhibited upregulation of apolipoprotein D (ApoD), apolipoprotein A1 (APOA1), apolipoprotein L (APOLD1), PPAR and very low-density apolipoprotein (VLDL) mRNA, alongside downregulation of occludin, which was further confirmed by increased VLDLR and PPAR-γ protein abundance and decreased occludin levels. In summary, our results revealed that the SWFs to SYFs transition proceeds with pronounced changes in transcriptional profiles associated with angiogenesis, sex steroid biosynthesis and yolk deposition. The increased steroid hormone production likely enhances the capacity for yolk synthesis. Furthermore, the elevated vascularization in the theca layer of SYFs in coupled with a reduction in tight junctions may facilitate the transport of yolk precursors to access the follicles. - Source: PubMed
Publication date: 2026/05/01
Ma YanfenZhou ShuoMi YulingZhang Caiqiao - Age-related macular degeneration (AMD) is a leading cause of irreversible blindness, primarily associated with retinal pigment epithelial (RPE) cell degeneration. Although RPE cell therapy has emerged as a promising strategy for AMD, maintaining RPE cell attachment, organization, and functional characteristics remains a major challenge. In this study, free-standing chondroitin sulfate (CS)/collagen (Col) multilayered films were fabricated via spin-coating-assisted layer-by-layer (LbL) assembly and evaluated in vitro as preliminary Bruch's membrane (BM)-mimetic platform for supporting RPE growth and preserving cellular functionality. Genipin cross-linking improved the mechanical stability of the films and reduced their swelling behavior. ARPE-19 cells cultured on the 2 h cross-linked films showed improved attachment and proliferation compared with uncross-linked films, together with detectable RPE65 expression and several RPE-related functional features, including apical-basal differences in pigment epithelium-derived factor (PEDF) secretion, phagocytosis of labeled photoreceptor outer segments (POS), and formation of microvilli-like structures. Collectively, these findings suggest that CS/Col free-standing films can support ARPE-19 cell growth and maintain several RPE-related phenotypic and functional features in vitro, providing a preliminary BM-mimetic platform for future RPE culture studies. - Source: PubMed
Publication date: 2026/05/02
Duo LanCheng PengfeiJiang WenpeiLin Quankui - The purpose of this study was to explore the protection of pigment epithelium-derived factor (PEDF) on the corneal endothelium in Fuchs endothelial corneal dystrophy (FECD). - Source: PubMed
Yao ShuangqingQiao YujieLin YujingSui XinZhou QingjunWang TingWang QunZhao Can - : Inherited retinal diseases (IRDs) represent a genetically heterogeneous group of disorders caused by mutations in over 280 genes with more than 3100 identified variants. While gene-specific replacement therapies have achieved landmark success with voretigene neparvovec (Luxturna) for biallelic -associated retinal dystrophy, developing individual therapies for each genetic subtype remains impractical. This review examines gene-agnostic therapeutic approaches utilizing neuroprotection and immunomodulation that target common pathophysiological mechanisms shared across multiple IRD genotypes. : We reviewed the literature on neuroprotective and immunomodulatory gene therapy strategies for IRDs, focusing on neurotrophic factors and complement system modulation. : Neuroprotective approaches delivering neurotrophic factors-including pigment epithelium-derived factor (PEDF), ciliary neurotrophic factor (CNTF), rod-derived cone viability factor (RdCVF), brain-derived neurotrophic factor (BDNF), fibroblast growth factors (FGFs), glial cell line-derived neurotrophic factor (GDNF), and proinsulin-have demonstrated photoreceptor preservation across multiple preclinical IRD models regardless of the underlying genetic mutation. The recent FDA approval of CNTF cell-based gene therapy (Encelto) for macular telangiectasia type 2 validates this therapeutic paradigm. Complement system inhibition represents another gene-agnostic strategy, with intravitreal complement inhibitors approved for geographic atrophy secondary to age-related macular degeneration and gene therapy approaches targeting C3, C5, or delivering soluble complement regulators under investigation for IRDs. Combination strategies simultaneously addressing multiple pathogenic pathways may offer synergistic benefits. : Gene-agnostic approaches targeting neuroprotection and immunomodulation offer a therapeutic paradigm capable of benefiting patients across the spectrum of IRD genotypes, potentially transforming treatment for conditions where mutation-specific therapies remain unavailable. - Source: PubMed
Publication date: 2026/03/30
Rowe Lucas WBecerra S PatriciaMacLaren Robert EAvery Robert LWykoff Charles CHo Allen CRegillo Carl DEliott DeanOsborne AndrewBinley Katie MCiulla Thomas A